- Partnering with multiple companies to develop targeted PET imaging tracers to better predict and monitor individual patient response to immunotherapies
- PET tracers would help increase patient response rates which currently average between 20-40%
- Initially PET tracers would support pharma companies to enhance clinical trials enabling speed-to-market for immunotherapies
Chalfont St Giles, UK –September 24 2019 – GE Healthcare is partnering with multiple companies and academic institutions to develo
For media inquiries, please contact:
David MorrisCommunications Director, Pharmaceutical Diagnostics
GE Healthcare
+44 7920591370
[email protected]
Europe/London